Quick Answer
Atara Biotherapeutics, Inc. reported Operating Income Loss of $35.86 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed an increase of +143.0% in Operating Income Loss from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2012: -$4.09 million | Q3 2013: -$2.55 million | Q1 2014: -$7.08 million | Q2 2014: -$4.53 million | Q3 2014: -$5.95 million | Q1 2015: -$9.31 million | Q2 2015: -$15.11 million | Q3 2015: -$12.26 million | Q1 2016: -$17.06 million | Q2 2016: -$19.49 million | Q3 2016: -$25.94 million | Q1 2017: -$26.16 million | Q2 2017: -$27.91 million | Q3 2017: -$31.66 million | Q1 2018: -$42.45 million | Q2 2018: -$52.62 million | Q3 2018: -$60.22 million | Q1 2019: -$67.89 million | Q2 2019: -$75.54 million | Q3 2019: -$72.56 million | Q1 2020: -$74.70 million | Q2 2020: -$77.95 million | Q3 2020: -$74.71 million | Q1 2021: -$78.25 million | Q2 2021: -$84.00 million | Q3 2021: -$84.81 million | Q1 2022: -$88.22 million | Q2 2022: -$32.13 million | Q3 2022: -$84.62 million | Q1 2023: -$75.02 million | Q2 2023: -$71.41 million | Q3 2023: -$69.61 million | Q1 2024: -$31.25 million | Q2 2024: -$18.23 million | Q3 2024: -$21.76 million | Q1 2025: $38.80 million | Q2 2025: $3.20 million | Q3 2025: -$3.57 million.
- Over the full 13 years of available data (2013 to 2025), Atara Biotherapeutics, Inc.'s Operating Income Loss has grown by 516.3%.
- Historical annual values: Fiscal year 2025: $35.86 million | Fiscal year 2024: -$83.44 million | Fiscal year 2023: -$276.01 million | Fiscal year 2022: -$280.51 million | Fiscal year 2021: -$340.46 million | Fiscal year 2020: -$309.05 million | Fiscal year 2019: -$295.68 million | Fiscal year 2018: -$237.11 million | Fiscal year 2017: -$121.53 million | Fiscal year 2016: -$81.24 million | Fiscal year 2015: -$58.45 million | Fiscal year 2014: -$28.16 million | Fiscal year 2013: -$8.62 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: